+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infliximab"

Global Infliximab Drug Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Infliximab Drug Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Oncology Market Forecast (2020-2025) - Product Thumbnail Image

Oncology Market Forecast (2020-2025)

  • Report
  • August 2020
  • 142 Pages
  • Global
From
From
Loading Indicator

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients. Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms. The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more